KNApSAcK Metabolite C00032464
Metabolite
KNApSAcK Entry
| id | C00032464 |
|---|---|
| Name | Ursodeoxycholic acid |
| CAS RN | 128-13-2 |
| Standard InChI | InChI=1S/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15+,16-,17-,18+,19+,20+,22+,23+,24-/m1/s1 |
| Standard InChI (Main Layer) | InChI=1S/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28) |
Cluster
| Phytochemical cluster | |
|---|---|
| KCF-S cluster | No. 2182 |
Link
ChEMBL
| By standard InChI | CHEMBL1551 |
|---|---|
| By standard InChI Main Layer | CHEMBL156266 CHEMBL240597 CHEMBL1551 CHEMBL1395373 CHEMBL1439625 CHEMBL1520183 CHEMBL1981518 CHEMBL1988085 CHEMBL2074643 |
KEGG
| By LinkDB | C07880 |
|---|
CTD
| By CAS RN | D014580 |
|---|
Human Protein / Gene in interaction
31 ChEMBL Protein in interactions
| accession | description | class description | compound | assay ID (# of activities) |
# of diseases
(OMIM / KEGG) |
|---|---|---|---|---|---|
| P10635 | Cytochrome P450 2D6 | Cytochrome P450 2D6 | CHEMBL1395373 CHEMBL1439625 |
CHEMBL1741321
(2)
|
1 / 0 |
| O75469 | Nuclear receptor subfamily 1 group I member 2 | NR1I2 | CHEMBL240597 CHEMBL1551 |
CHEMBL901722
(2)
CHEMBL901723
(2)
|
0 / 0 |
| P49798 | Regulator of G-protein signaling 4 | Unclassified protein | CHEMBL240597 |
CHEMBL1794499
(1)
|
2 / 0 |
| O95342 | Bile salt export pump | drug | CHEMBL240597 CHEMBL2074643 |
CHEMBL1027010
(1)
CHEMBL2077353
(1)
|
2 / 1 |
| P04062 | Glucosylceramidase | Enzyme | CHEMBL1520183 |
CHEMBL1613818
(1)
|
6 / 4 |
| Q8TDU6 | G-protein coupled bile acid receptor 1 | Steroid-like ligand receptor | CHEMBL240597 CHEMBL1551 |
CHEMBL895767
(1)
CHEMBL895768
(1)
CHEMBL901743 (2) CHEMBL949256 (2) CHEMBL949257 (2) CHEMBL1768539 (1) CHEMBL2065430 (1) CHEMBL2065431 (1) |
0 / 0 |
| P02545 | Prelamin-A/C | Unclassified protein | CHEMBL1439625 |
CHEMBL1614544
(1)
|
11 / 10 |
| P37840 | Alpha-synuclein | Unclassified protein | CHEMBL1551 |
CHEMBL2354282
(1)
|
4 / 2 |
| P02768 | Serum albumin | Secreted protein | CHEMBL240597 |
CHEMBL1043247
(1)
CHEMBL2065437
(1)
|
0 / 0 |
| P11712 | Cytochrome P450 2C9 | Cytochrome P450 2C9 | CHEMBL1395373 CHEMBL1439625 |
CHEMBL1741325
(2)
|
0 / 1 |
| Q14973 | Sodium/bile acid cotransporter | Bile acid | CHEMBL1551 CHEMBL2074643 |
CHEMBL2077659
(1)
CHEMBL2075344
(1)
CHEMBL2078145 (1) CHEMBL2077873 (1) |
0 / 0 |
| Q12908 | Ileal sodium/bile acid cotransporter | Bile acid | CHEMBL1551 CHEMBL2074643 |
CHEMBL2076042
(2)
|
1 / 1 |
| O75496 | Geminin | Unclassified protein | CHEMBL1551 |
CHEMBL2114780
(1)
|
0 / 0 |
| P46721 | Solute carrier organic anion transporter family member 1A2 | Unclassified protein | CHEMBL1551 CHEMBL2074643 |
CHEMBL2076544
(1)
CHEMBL2076572
(1)
CHEMBL2076720 (1) CHEMBL2077886 (1) |
0 / 0 |
| O15439 | Multidrug resistance-associated protein 4 | Unclassified protein | CHEMBL1551 |
CHEMBL2078609
(1)
|
0 / 0 |
| P63092 | Guanine nucleotide-binding protein G(s) subunit alpha isoforms short | Other membrane protein | CHEMBL240597 CHEMBL1551 |
CHEMBL2114817
(2)
|
7 / 3 |
| P83916 | Chromobox protein homolog 1 | Unclassified protein | CHEMBL240597 CHEMBL1551 |
CHEMBL1794401
(2)
|
0 / 0 |
| P04150 | Glucocorticoid receptor | NR3C1 | CHEMBL1551 |
CHEMBL1657195
(1)
CHEMBL1657196
(1)
CHEMBL1657200 (1) CHEMBL1657201 (1) CHEMBL1657202 (1) CHEMBL1657204 (1) |
0 / 1 |
| Q96RI1 | Bile acid receptor | NR1H4 | CHEMBL240597 CHEMBL1551 |
CHEMBL682032
(1)
CHEMBL682033
(1)
CHEMBL682034 (1) CHEMBL681096 (1) CHEMBL680578 (1) CHEMBL680579 (1) CHEMBL828943 (1) CHEMBL829871 (1) CHEMBL831813 (1) CHEMBL835612 (1) CHEMBL866367 (1) CHEMBL854499 (2) CHEMBL871522 (1) CHEMBL892388 (1) CHEMBL892391 (1) CHEMBL895769 (1) CHEMBL895770 (1) CHEMBL901725 (2) CHEMBL901726 (2) CHEMBL949258 (2) CHEMBL949259 (1) CHEMBL992475 (1) CHEMBL992476 (1) CHEMBL1027008 (1) CHEMBL1027009 (1) CHEMBL1043241 (1) CHEMBL1694299 (1) CHEMBL1694417 (1) CHEMBL1694424 (1) CHEMBL1768535 (1) CHEMBL1768540 (1) CHEMBL1768541 (1) CHEMBL1768542 (1) CHEMBL1768543 (1) CHEMBL1768544 (1) CHEMBL1768545 (1) CHEMBL1768546 (1) CHEMBL1768547 (1) CHEMBL1921084 (1) CHEMBL1921086 (1) CHEMBL1932588 (1) CHEMBL1954170 (1) CHEMBL2025894 (1) CHEMBL2025895 (1) CHEMBL2025896 (1) CHEMBL2025897 (1) CHEMBL2025898 (1) CHEMBL2025899 (1) CHEMBL2025900 (1) CHEMBL2034293 (1) CHEMBL2034294 (1) CHEMBL2034295 (1) CHEMBL2061934 (1) CHEMBL2061937 (1) CHEMBL2061940 (1) CHEMBL2061984 (1) CHEMBL2065432 (1) CHEMBL2065433 (1) CHEMBL2213585 (1) CHEMBL2214033 (1) |
0 / 0 |
| P05177 | Cytochrome P450 1A2 | Cytochrome P450 1A2 | CHEMBL1395373 CHEMBL1439625 |
CHEMBL1741322
(2)
|
0 / 0 |
| Q92887 | Canalicular multispecific organic anion transporter 1 | Unclassified protein | CHEMBL240597 CHEMBL2074643 |
CHEMBL1006005
(1)
CHEMBL2075334
(1)
|
1 / 1 |
| P06133 | UDP-glucuronosyltransferase 2B4 | Enzyme | CHEMBL240597 CHEMBL1551 |
CHEMBL1908092
(6)
|
0 / 0 |
| P33261 | Cytochrome P450 2C19 | Cytochrome P450 2C19 | CHEMBL1395373 CHEMBL1439625 |
CHEMBL1613777
(1)
CHEMBL1741323
(2)
|
1 / 1 |
| P08684 | Cytochrome P450 3A4 | Cytochrome P450 3A4 | CHEMBL1395373 CHEMBL1439625 CHEMBL1520183 |
CHEMBL1614108
(1)
CHEMBL1613886
(1)
CHEMBL1741324 (2) |
0 / 1 |
| P08235 | Mineralocorticoid receptor | NR3C2 | CHEMBL1551 |
CHEMBL1657203
(1)
|
2 / 2 |
| P04054 | Phospholipase A2 | Enzyme | CHEMBL240597 |
CHEMBL1026212
(1)
CHEMBL1026996
(1)
CHEMBL1027004 (1) |
0 / 0 |
| Q9UBT6 | DNA polymerase kappa | Enzyme | CHEMBL1520183 |
CHEMBL1794536
(1)
|
0 / 0 |
| Q9NUW8 | Tyrosyl-DNA phosphodiesterase 1 | Enzyme | CHEMBL240597 |
CHEMBL1614364
(1)
|
1 / 1 |
| O00255 | Menin | Unclassified protein | CHEMBL240597 CHEMBL1439625 |
CHEMBL1614257
(1)
CHEMBL1614531
(1)
|
2 / 5 |
| Q03164 | Histone-lysine N-methyltransferase 2A | Enzyme | CHEMBL240597 CHEMBL1439625 |
CHEMBL1614257
(1)
CHEMBL1614531
(1)
|
1 / 3 |
| Q13148 | TAR DNA-binding protein 43 | Unclassified protein | CHEMBL240597 CHEMBL1551 |
CHEMBL2354287
(2)
|
1 / 1 |
CTD interaction (245)
| compound | gene | gene name | gene description | interaction | interaction type | form |
reference
pmid |
|---|---|---|---|---|---|---|---|
| D014580 | 5243 |
ABCB1
ABC20 CD243 CLCS GP170 MDR1 P-GP PGY1 |
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) | Ursodeoxycholic Acid results in increased expression of ABCB1 mRNA |
increases expression
|
mRNA |
16678547
|
| D014580 | 8647 |
ABCB11
ABC16 BRIC2 BSEP PFIC-2 PFIC2 PGY4 SPGP |
ATP-binding cassette, sub-family B (MDR/TAP), member 11 | Ursodeoxycholic Acid results in increased expression of ABCB11 mRNA |
increases expression
|
mRNA |
14684751
|
| D014580 | 1244 |
ABCC2
ABC30 CMOAT DJS MRP2 cMRP |
ATP-binding cassette, sub-family C (CFTR/MRP), member 2 | Ursodeoxycholic Acid results in increased expression of ABCC2 |
increases expression
|
16952291
|
|
| D014580 | 1244 |
ABCC2
ABC30 CMOAT DJS MRP2 cMRP |
ATP-binding cassette, sub-family C (CFTR/MRP), member 2 | Ursodeoxycholic Acid results in increased expression of ABCC2 protein |
increases expression
|
protein |
15956029
|
| D014580 | 1645 |
AKR1C1
2-ALPHA-HSD 20-ALPHA-HSD C9 DD1 DD1/DD2 DDH DDH1 H-37 HAKRC HBAB MBAB |
aldo-keto reductase family 1, member C1 (EC:1.3.1.20 1.1.1.149 1.1.1.112) | Ursodeoxycholic Acid results in decreased activity of AKR1C1 protein |
decreases activity
|
protein |
12604236
|
| D014580 | 1646 |
AKR1C2
AKR1C-pseudo BABP DD DD2 DDH2 HAKRD HBAB MCDR2 SRXY8 |
aldo-keto reductase family 1, member C2 (EC:1.3.1.20 1.1.1.357) | Ursodeoxycholic Acid results in decreased activity of AKR1C2 protein |
decreases activity
|
protein |
8573067
12604236 |
| D014580 | 8644 |
AKR1C3
DD3 DDX HA1753 HAKRB HAKRe HSD17B5 PGFS hluPGFS |
aldo-keto reductase family 1, member C3 (EC:1.3.1.20 1.1.1.188 1.1.1.239 1.1.1.64 1.1.1.112 1.1.1.357) | Ursodeoxycholic Acid results in decreased activity of AKR1C3 protein |
decreases activity
|
protein |
12604236
|
| D014580 | 207 |
AKT1
AKT CWS6 PKB PKB-ALPHA PRKBA RAC RAC-ALPHA |
v-akt murine thymoma viral oncogene homolog 1 (EC:2.7.11.1) | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Ursodeoxycholic Acid results in increased phosphorylation of AKT1 protein] |
decreases reaction
/ increases phosphorylation |
protein |
19073151
|
| D014580 | 207 |
AKT1
AKT CWS6 PKB PKB-ALPHA PRKBA RAC RAC-ALPHA |
v-akt murine thymoma viral oncogene homolog 1 (EC:2.7.11.1) | Ursodeoxycholic Acid results in increased phosphorylation of AKT1 protein |
increases phosphorylation
|
protein |
19073151
|
| D014580 | 23243 |
ANKRD28
PITK PPP1R65 |
ankyrin repeat domain 28 | Ursodeoxycholic Acid affects the expression of ANKRD28 mRNA |
affects expression
|
mRNA |
18422935
|
| D014580 | 1173 |
AP2M1
AP50 CLAPM1 mu2 |
adaptor-related protein complex 2, mu 1 subunit | Ursodeoxycholic Acid affects the expression of AP2M1 mRNA |
affects expression
|
mRNA |
18422935
|
| D014580 | 335 |
APOA1
|
apolipoprotein A-I | Ursodeoxycholic Acid results in increased expression of APOA1 mRNA |
increases expression
|
mRNA |
15115973
|
| D014580 | 55937 |
APOM
G3a HSPC336 NG20 apo-M |
apolipoprotein M | Ursodeoxycholic Acid inhibits the reaction [Simvastatin results in increased expression of APOM mRNA] |
decreases reaction
/ increases expression |
mRNA |
22160096
|
| D014580 | 55937 |
APOM
G3a HSPC336 NG20 apo-M |
apolipoprotein M | Ursodeoxycholic Acid inhibits the reaction [Simvastatin results in increased expression of APOM protein] |
decreases reaction
/ increases expression |
protein |
22160096
|
| D014580 | 581 |
BAX
BCL2L4 |
BCL2-associated X protein | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Ursodeoxycholic Acid inhibits the reaction [Nitroprusside affects the localization of BAX protein]] |
affects localization
/ decreases reaction |
protein |
22178905
|
| D014580 | 581 |
BAX
BCL2L4 |
BCL2-associated X protein | triciribine inhibits the reaction [Ursodeoxycholic Acid inhibits the reaction [Nitroprusside affects the localization of BAX protein]] |
affects localization
/ decreases reaction |
protein |
22178905
|
| D014580 | 581 |
BAX
BCL2L4 |
BCL2-associated X protein | Ursodeoxycholic Acid inhibits the reaction [Nitroprusside results in increased expression of and affects the localization of BAX protein] |
affects localization
/ decreases reaction / increases expression |
protein |
22178905
|
| D014580 | 581 |
BAX
BCL2L4 |
BCL2-associated X protein | Ursodeoxycholic Acid results in increased expression of BAX |
increases expression
|
17461466
|
|
| D014580 | 596 |
BCL2
Bcl-2 PPP1R50 |
B-cell CLL/lymphoma 2 | Ursodeoxycholic Acid results in decreased expression of BCL2 |
decreases expression
|
17461466
|
|
| D014580 | 644 |
BLVRA
BLVR BVR BVRA |
biliverdin reductase A (EC:1.3.1.24) | Ursodeoxycholic Acid results in increased expression of BLVRA mRNA |
increases expression
|
mRNA |
18706437
|
| D014580 | 722 |
C4BPA
C4BP PRP |
complement component 4 binding protein, alpha | Ursodeoxycholic Acid affects the expression of C4BPA mRNA |
affects expression
|
mRNA |
18422935
|
| D014580 | 836 |
CASP3
CPP32 CPP32B SCA-1 |
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) | benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [[oxaliplatin co-treated with Ursodeoxycholic Acid] results in increased activity of CASP3 protein] |
affects cotreatment
/ decreases reaction / increases activity |
protein |
19728331
|
| D014580 | 836 |
CASP3
CPP32 CPP32B SCA-1 |
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) | benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Ursodeoxycholic Acid results in increased cleavage of and results in increased activity of CASP3 protein] |
decreases reaction
/ increases activity / increases cleavage |
protein |
21362627
|
| D014580 | 836 |
CASP3
CPP32 CPP32B SCA-1 |
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) | FADD mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased cleavage of CASP3 protein] |
decreases reaction
/ increases cleavage |
protein |
21362627
|
| D014580 | 836 |
CASP3
CPP32 CPP32B SCA-1 |
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) | methyl-beta-cyclodextrin inhibits the reaction [Ursodeoxycholic Acid results in increased cleavage of CASP3 protein] |
decreases reaction
/ increases cleavage |
protein |
21362627
|
| D014580 | 836 |
CASP3
CPP32 CPP32B SCA-1 |
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) | [oxaliplatin co-treated with Ursodeoxycholic Acid] results in increased activity of CASP3 protein |
affects cotreatment
/ increases activity |
protein |
19728331
|
| D014580 | 836 |
CASP3
CPP32 CPP32B SCA-1 |
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) | pifithrin inhibits the reaction [[oxaliplatin co-treated with Ursodeoxycholic Acid] results in increased activity of CASP3 protein] |
affects cotreatment
/ decreases reaction / increases activity |
protein |
19728331
|
| D014580 | 836 |
CASP3
CPP32 CPP32B SCA-1 |
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) | RIPK1 mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased cleavage of CASP3 protein] |
decreases reaction
/ increases cleavage |
protein |
21362627
|
| D014580 | 836 |
CASP3
CPP32 CPP32B SCA-1 |
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) | rottlerin inhibits the reaction [Ursodeoxycholic Acid results in increased cleavage of CASP3 protein] |
decreases reaction
/ increases cleavage |
protein |
21362627
|
| D014580 | 836 |
CASP3
CPP32 CPP32B SCA-1 |
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) | TNFRSF10B mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased cleavage of CASP3 protein] |
decreases reaction
/ increases cleavage |
protein |
21362627
|
| D014580 | 836 |
CASP3
CPP32 CPP32B SCA-1 |
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) | TP53 mutant form inhibits the reaction [[oxaliplatin co-treated with Ursodeoxycholic Acid] results in increased activity of CASP3 protein] |
affects cotreatment
/ decreases reaction / increases activity |
protein |
19728331
|
| D014580 | 836 |
CASP3
CPP32 CPP32B SCA-1 |
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) | Ursodeoxycholic Acid analog inhibits the reaction [TNF protein results in increased activity of CASP3 protein] |
decreases reaction
/ increases activity |
protein |
21146893
|
| D014580 | 836 |
CASP3
CPP32 CPP32B SCA-1 |
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) | Ursodeoxycholic Acid inhibits the reaction [Nitroprusside results in increased activity of CASP3 protein] |
decreases reaction
/ increases activity |
protein |
22178905
|
| D014580 | 836 |
CASP3
CPP32 CPP32B SCA-1 |
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) | Ursodeoxycholic Acid promotes the reaction [irinotecan results in increased activity of CASP3 protein] |
increases activity
/ increases reaction |
protein |
16432164
|
| D014580 | 836 |
CASP3
CPP32 CPP32B SCA-1 |
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) | Ursodeoxycholic Acid results in increased cleavage of and results in increased activity of CASP3 protein |
increases activity
/ increases cleavage |
protein |
21362627
|
| D014580 | 839 |
CASP6
MCH2 |
caspase 6, apoptosis-related cysteine peptidase (EC:3.4.22.59) | benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Ursodeoxycholic Acid results in increased cleavage of and results in increased activity of CASP6 protein] |
decreases reaction
/ increases activity / increases cleavage |
protein |
21362627
|
| D014580 | 839 |
CASP6
MCH2 |
caspase 6, apoptosis-related cysteine peptidase (EC:3.4.22.59) | FADD mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased cleavage of CASP6 protein] |
decreases reaction
/ increases cleavage |
protein |
21362627
|
| D014580 | 839 |
CASP6
MCH2 |
caspase 6, apoptosis-related cysteine peptidase (EC:3.4.22.59) | methyl-beta-cyclodextrin inhibits the reaction [Ursodeoxycholic Acid results in increased cleavage of CASP6 protein] |
decreases reaction
/ increases cleavage |
protein |
21362627
|
| D014580 | 839 |
CASP6
MCH2 |
caspase 6, apoptosis-related cysteine peptidase (EC:3.4.22.59) | RIPK1 mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased cleavage of CASP6 protein] |
decreases reaction
/ increases cleavage |
protein |
21362627
|
| D014580 | 839 |
CASP6
MCH2 |
caspase 6, apoptosis-related cysteine peptidase (EC:3.4.22.59) | rottlerin inhibits the reaction [Ursodeoxycholic Acid results in increased cleavage of CASP6 protein] |
decreases reaction
/ increases cleavage |
protein |
21362627
|
| D014580 | 839 |
CASP6
MCH2 |
caspase 6, apoptosis-related cysteine peptidase (EC:3.4.22.59) | TNFRSF10B mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased cleavage of CASP6 protein] |
decreases reaction
/ increases cleavage |
protein |
21362627
|
| D014580 | 839 |
CASP6
MCH2 |
caspase 6, apoptosis-related cysteine peptidase (EC:3.4.22.59) | Ursodeoxycholic Acid results in increased cleavage of and results in increased activity of CASP6 protein |
increases activity
/ increases cleavage |
protein |
21362627
|
| D014580 | 840 |
CASP7
CASP-7 CMH-1 ICE-LAP3 LICE2 MCH3 |
caspase 7, apoptosis-related cysteine peptidase (EC:3.4.22.60) | Ursodeoxycholic Acid analog inhibits the reaction [TNF protein results in increased activity of CASP7 protein] |
decreases reaction
/ increases activity |
protein |
21146893
|
| D014580 | 840 |
CASP7
CASP-7 CMH-1 ICE-LAP3 LICE2 MCH3 |
caspase 7, apoptosis-related cysteine peptidase (EC:3.4.22.60) | Ursodeoxycholic Acid inhibits the reaction [Nitroprusside results in increased activity of CASP7 protein] |
decreases reaction
/ increases activity |
protein |
22178905
|
| D014580 | 841 |
CASP8
ALPS2B CAP4 Casp-8 FLICE MACH MCH5 |
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) | FADD mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased activity of CASP8 protein] |
decreases reaction
/ increases activity |
protein |
21362627
|
| D014580 | 841 |
CASP8
ALPS2B CAP4 Casp-8 FLICE MACH MCH5 |
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) | [oxaliplatin co-treated with Ursodeoxycholic Acid] results in increased cleavage of and results in increased activity of CASP8 protein |
affects cotreatment
/ increases activity / increases cleavage |
protein |
19728331
|
| D014580 | 841 |
CASP8
ALPS2B CAP4 Casp-8 FLICE MACH MCH5 |
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) | pifithrin inhibits the reaction [[oxaliplatin co-treated with Ursodeoxycholic Acid] results in increased activity of CASP8 protein] |
affects cotreatment
/ decreases reaction / increases activity |
protein |
19728331
|
| D014580 | 841 |
CASP8
ALPS2B CAP4 Casp-8 FLICE MACH MCH5 |
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) | RIPK1 mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased activity of CASP8 protein] |
decreases reaction
/ increases activity |
protein |
21362627
|
| D014580 | 841 |
CASP8
ALPS2B CAP4 Casp-8 FLICE MACH MCH5 |
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) | TNFRSF10B mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased activity of CASP8 protein] |
decreases reaction
/ increases activity |
protein |
21362627
|
| D014580 | 841 |
CASP8
ALPS2B CAP4 Casp-8 FLICE MACH MCH5 |
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) | TP53 mutant form inhibits the reaction [[oxaliplatin co-treated with Ursodeoxycholic Acid] results in increased activity of CASP8 protein] |
affects cotreatment
/ decreases reaction / increases activity |
protein |
19728331
|
| D014580 | 841 |
CASP8
ALPS2B CAP4 Casp-8 FLICE MACH MCH5 |
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) | Ursodeoxycholic Acid promotes the reaction [irinotecan results in increased activity of CASP8 protein] |
increases activity
/ increases reaction |
protein |
16432164
|
| D014580 | 841 |
CASP8
ALPS2B CAP4 Casp-8 FLICE MACH MCH5 |
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) | Ursodeoxycholic Acid results in increased activity of CASP8 protein |
increases activity
|
protein |
21362627
|
| D014580 | 842 |
CASP9
APAF-3 APAF3 ICE-LAP6 MCH6 PPP1R56 |
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) | Ursodeoxycholic Acid inhibits the reaction [Nitroprusside results in increased activity of CASP9 protein] |
decreases reaction
/ increases activity |
protein |
22178905
|
| D014580 | 6347 |
CCL2
GDCF-2 HC11 HSMCR30 MCAF MCP-1 MCP1 SCYA2 SMC-CF |
chemokine (C-C motif) ligand 2 | Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL2 mRNA]] |
decreases reaction
/ increases expression / increases reaction |
mRNA |
21146893
|
| D014580 | 6352 |
CCL5
D17S136E RANTES SCYA5 SIS-delta SISd TCP228 eoCP |
chemokine (C-C motif) ligand 5 | Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL5 mRNA]] |
decreases reaction
/ increases expression / increases reaction |
mRNA |
21146893
|
| D014580 | 595 |
CCND1
BCL1 D11S287E PRAD1 U21B31 |
cyclin D1 | Ursodeoxycholic Acid results in decreased expression of CCND1 protein |
decreases expression
|
protein |
17461466
|
| D014580 | 896 |
CCND3
|
cyclin D3 | Ursodeoxycholic Acid results in decreased expression of CCND3 protein |
decreases expression
|
protein |
17461466
|
| D014580 | 7203 |
CCT3
CCT-gamma CCTG PIG48 TCP-1-gamma TRIC5 |
chaperonin containing TCP1, subunit 3 (gamma) | Ursodeoxycholic Acid affects the expression of CCT3 mRNA |
affects expression
|
mRNA |
18422935
|
| D014580 | 22948 |
CCT5
CCT-epsilon CCTE TCP-1-epsilon |
chaperonin containing TCP1, subunit 5 (epsilon) | Ursodeoxycholic Acid affects the expression of CCT5 mRNA |
affects expression
|
mRNA |
18422935
|
| D014580 | 57124 |
CD248
CD164L1 TEM1 |
CD248 molecule, endosialin | Ursodeoxycholic Acid affects the expression of CD248 mRNA |
affects expression
|
mRNA |
18422935
|
| D014580 | 1051 |
CEBPB
C/EBP-beta CRP2 IL6DBP LAP LIP NF-IL6 TCF5 |
CCAAT/enhancer binding protein (C/EBP), beta | Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased expression of CEBPB] |
decreases reaction
/ increases expression |
18444174
|
|
| D014580 | 8837 |
CFLAR
CASH CASP8AP1 CLARP Casper FLAME FLAME-1 FLAME1 FLIP I-FLICE MRIT c-FLIP c-FLIPL c-FLIPR c-FLIPS |
CASP8 and FADD-like apoptosis regulator | Ursodeoxycholic Acid analog results in increased expression of CFLAR protein |
increases expression
|
protein |
21146893
|
| D014580 | 1267 |
CNP
CNP1 |
2',3'-cyclic nucleotide 3' phosphodiesterase (EC:3.1.4.37) | Ursodeoxycholic Acid affects the expression of CNP mRNA |
affects expression
|
mRNA |
18422935
|
| D014580 | 1434 |
CSE1L
CAS CSE1 XPO2 |
CSE1 chromosome segregation 1-like (yeast) | Ursodeoxycholic Acid affects the expression of CSE1L mRNA |
affects expression
|
mRNA |
18422935
|
| D014580 | 1464 |
CSPG4
HMW-MAA MCSP MCSPG MEL-CSPG MSK16 NG2 |
chondroitin sulfate proteoglycan 4 | Ursodeoxycholic Acid affects the expression of CSPG4 mRNA |
affects expression
|
mRNA |
18422935
|
| D014580 | 1543 |
CYP1A1
AHH AHRR CP11 CYP1 P1-450 P450-C P450DX |
cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) | Ursodeoxycholic Acid inhibits the reaction [benzo(a)pyrene 7,8-dihydrodiol results in increased expression of CYP1A1 mRNA] |
decreases reaction
/ increases expression |
mRNA |
10706104
|
| D014580 | 1576 |
CYP3A4
CP33 CP34 CYP3A CYP3A3 CYPIIIA3 CYPIIIA4 HLP NF-25 P450C3 P450PCN1 |
cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | CYP3A4 protein affects the metabolism of Ursodeoxycholic Acid |
affects metabolic processing
|
protein |
15708356
|
| D014580 | 1576 |
CYP3A4
CP33 CP34 CYP3A CYP3A3 CYPIIIA3 CYPIIIA4 HLP NF-25 P450C3 P450PCN1 |
cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | Ursodeoxycholic Acid results in increased expression of CYP3A4 mRNA |
increases expression
|
mRNA |
16678547
|
| D014580 | 1581 |
CYP7A1
CP7A CYP7 CYPVII |
cytochrome P450, family 7, subfamily A, polypeptide 1 (EC:1.14.13.17) | Tretinoin promotes the reaction [Ursodeoxycholic Acid results in decreased expression of CYP7A1 mRNA] |
decreases expression
/ increases reaction |
mRNA |
21274875
|
| D014580 | 1581 |
CYP7A1
CP7A CYP7 CYPVII |
cytochrome P450, family 7, subfamily A, polypeptide 1 (EC:1.14.13.17) | Ursodeoxycholic Acid promotes the reaction [Tretinoin results in decreased expression of CYP7A1 mRNA] |
decreases expression
/ increases reaction |
mRNA |
21274875
|
| D014580 | 1581 |
CYP7A1
CP7A CYP7 CYPVII |
cytochrome P450, family 7, subfamily A, polypeptide 1 (EC:1.14.13.17) | Ursodeoxycholic Acid results in decreased expression of CYP7A1 mRNA |
decreases expression
|
mRNA |
14684751
21274875 |
| D014580 | 7818 |
DAP3
DAP-3 MRP-S29 MRPS29 bMRP-10 |
death associated protein 3 | Ursodeoxycholic Acid affects the expression of DAP3 mRNA |
affects expression
|
mRNA |
18422935
|
| D014580 | 1660 |
DHX9
DDX9 LKP NDH2 NDHII RHA |
DEAH (Asp-Glu-Ala-His) box helicase 9 (EC:3.6.4.13) | Ursodeoxycholic Acid affects the expression of DHX9 mRNA |
affects expression
|
mRNA |
18422935
|
| D014580 | 1737 |
DLAT
DLTA PDC-E2 PDCE2 |
dihydrolipoamide S-acetyltransferase (EC:2.3.1.12) | Ursodeoxycholic Acid affects the expression of DLAT mRNA |
affects expression
|
mRNA |
18422935
|
| D014580 | 10395 |
DLC1
ARHGAP7 HP STARD12 p122-RhoGAP |
deleted in liver cancer 1 | DLC1 mutant form inhibits the reaction [Ursodeoxycholic Acid results in decreased activity of RHOA protein] |
decreases activity
/ decreases reaction |
mutant form |
21455586
|
| D014580 | 10395 |
DLC1
ARHGAP7 HP STARD12 p122-RhoGAP |
deleted in liver cancer 1 | Ursodeoxycholic Acid results in increased expression of DLC1 protein |
increases expression
|
protein |
21455586
|
| D014580 | 1906 |
EDN1
ET1 HDLCQ7 PPET1 |
endothelin 1 | Ursodeoxycholic Acid results in decreased expression of EDN1 mRNA |
decreases expression
|
mRNA |
15556138
|
| D014580 | 1906 |
EDN1
ET1 HDLCQ7 PPET1 |
endothelin 1 | Ursodeoxycholic Acid results in decreased expression of EDN1 protein |
decreases expression
|
protein |
15556138
|
| D014580 | 1907 |
EDN2
ET2 PPET2 |
endothelin 2 | Ursodeoxycholic Acid results in decreased expression of EDN2 protein |
decreases expression
|
protein |
15691296
|
| D014580 | 1956 |
EGFR
ERBB ERBB1 HER1 PIG61 mENA |
epidermal growth factor receptor (EC:2.7.10.1) | Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased phosphorylation of EGFR protein] |
decreases reaction
/ increases phosphorylation |
protein |
14747693
|
| D014580 | 10209 |
EIF1
A121 EIF-1 EIF1A ISO1 SUI1 |
eukaryotic translation initiation factor 1 | Ursodeoxycholic Acid affects the expression of EIF1 mRNA |
affects expression
|
mRNA |
18422935
|
| D014580 | 2033 |
EP300
KAT3B RSTS2 p300 |
E1A binding protein p300 (EC:2.3.1.48) | [Ursodeoxycholic Acid co-treated with Dexamethasone] promotes the reaction [EP300 protein binds to GR1 protein binds to HNF1A protein binds to SLC4A2 promoter alternative form] |
affects binding
/ affects cotreatment / increases reaction |
protein |
18188457
|
| D014580 | 2033 |
EP300
KAT3B RSTS2 p300 |
E1A binding protein p300 (EC:2.3.1.48) | [Ursodeoxycholic Acid co-treated with Dexamethasone] promotes the reaction [EP300 protein binds to SLC4A2 promoter] |
affects binding
/ affects cotreatment / increases reaction |
protein |
18188457
|
| D014580 | 2033 |
EP300
KAT3B RSTS2 p300 |
E1A binding protein p300 (EC:2.3.1.48) | [Ursodeoxycholic Acid co-treated with Dexamethasone] promotes the reaction [EP300 protein binds to SLC4A2 promoter alternative form] |
affects binding
/ affects cotreatment / increases reaction |
protein |
18188457
|
| D014580 | 2033 |
EP300
KAT3B RSTS2 p300 |
E1A binding protein p300 (EC:2.3.1.48) | [Ursodeoxycholic Acid co-treated with Dexamethasone] promotes the reaction [HNF1B protein binds to GR1 protein binds to EP300 protein binds to SLC4A2 promoter alternative form] |
affects binding
/ affects cotreatment / increases reaction |
protein |
18188457
|
| D014580 | 2033 |
EP300
KAT3B RSTS2 p300 |
E1A binding protein p300 (EC:2.3.1.48) | Ursodeoxycholic Acid promotes the reaction [EP300 protein binds to SLC4A2 promoter] |
affects binding
/ increases reaction |
protein |
18188457
|
| D014580 | 79956 |
ERMP1
FXNA KIAA1815 bA207C16.3 |
endoplasmic reticulum metallopeptidase 1 | Ursodeoxycholic Acid affects the expression of ERMP1 mRNA |
affects expression
|
mRNA |
18422935
|
| D014580 | 2172 |
FABP6
I-15P I-BABP I-BALB I-BAP ILBP ILBP3 ILLBP |
fatty acid binding protein 6, ileal | Ursodeoxycholic Acid inhibits the reaction [Chenodeoxycholic Acid results in increased expression of FABP6 mRNA] |
decreases reaction
/ increases expression |
mRNA |
15935148
|
| D014580 | 2172 |
FABP6
I-15P I-BABP I-BALB I-BAP ILBP ILBP3 ILLBP |
fatty acid binding protein 6, ileal | Ursodeoxycholic Acid results in increased expression of FABP6 mRNA |
increases expression
|
mRNA |
15935148
|
| D014580 | 8772 |
FADD
MORT1 |
Fas (TNFRSF6)-associated via death domain | FADD mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased activity of CASP8 protein] |
decreases reaction
/ increases activity |
mutant form |
21362627
|
| D014580 | 8772 |
FADD
MORT1 |
Fas (TNFRSF6)-associated via death domain | FADD mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased cleavage of CASP3 protein] |
decreases reaction
/ increases cleavage |
mutant form |
21362627
|
| D014580 | 8772 |
FADD
MORT1 |
Fas (TNFRSF6)-associated via death domain | FADD mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased cleavage of CASP6 protein] |
decreases reaction
/ increases cleavage |
mutant form |
21362627
|
| D014580 | 8772 |
FADD
MORT1 |
Fas (TNFRSF6)-associated via death domain | FADD mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased cleavage of PARP1 protein] |
decreases reaction
/ increases cleavage |
mutant form |
21362627
|
| D014580 | 26049 |
FAM169A
SLAP75 |
family with sequence similarity 169, member A | Ursodeoxycholic Acid affects the expression of FAM169A mRNA |
affects expression
|
mRNA |
18422935
|
| D014580 | 54537 |
FAM35A
FAM35A1 bA163M19.1 |
family with sequence similarity 35, member A | Ursodeoxycholic Acid affects the expression of FAM35A mRNA |
affects expression
|
mRNA |
18422935
|
| D014580 | 9965 |
FGF19
|
fibroblast growth factor 19 | Ursodeoxycholic Acid promotes the reaction [Tretinoin results in increased expression of FGF19 mRNA] |
increases expression
/ increases reaction |
mRNA |
21274875
|
| D014580 | 2266 |
FGG
|
fibrinogen gamma chain | Ursodeoxycholic Acid affects the expression of FGG mRNA |
affects expression
|
mRNA |
18422935
|
| D014580 | 2267 |
FGL1
HFREP1 HP-041 LFIRE-1 LFIRE1 |
fibrinogen-like 1 | Ursodeoxycholic Acid affects the expression of FGL1 mRNA |
affects expression
|
mRNA |
18422935
|
| D014580 | 2617 |
GARS
CMT2D DSMAV GlyRS HMN5 SMAD1 |
glycyl-tRNA synthetase (EC:6.1.1.14) | Ursodeoxycholic Acid affects the expression of GARS mRNA |
affects expression
|
mRNA |
18422935
|
| D014580 | 2729 |
GCLC
GCL GCS GLCL GLCLC |
glutamate-cysteine ligase, catalytic subunit (EC:6.3.2.2) | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Ursodeoxycholic Acid results in increased expression of GCLC mRNA] |
decreases reaction
/ increases expression |
mRNA |
19073151
|
| D014580 | 2729 |
GCLC
GCL GCS GLCL GLCLC |
glutamate-cysteine ligase, catalytic subunit (EC:6.3.2.2) | Ursodeoxycholic Acid inhibits the reaction [Iron results in decreased expression of GCLC mRNA] |
decreases expression
/ decreases reaction |
mRNA |
19073151
|
| D014580 | 2729 |
GCLC
GCL GCS GLCL GLCLC |
glutamate-cysteine ligase, catalytic subunit (EC:6.3.2.2) | Ursodeoxycholic Acid results in increased expression of GCLC mRNA |
increases expression
|
mRNA |
19073151
|
| D014580 | 2730 |
GCLM
GLCLR |
glutamate-cysteine ligase, modifier subunit (EC:6.3.2.2) | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Ursodeoxycholic Acid results in increased expression of GCLM mRNA] |
decreases reaction
/ increases expression |
mRNA |
19073151
|
| D014580 | 2730 |
GCLM
GLCLR |
glutamate-cysteine ligase, modifier subunit (EC:6.3.2.2) | Ursodeoxycholic Acid inhibits the reaction [Iron results in decreased expression of GCLM mRNA] |
decreases expression
/ decreases reaction |
mRNA |
19073151
|
| D014580 | 2730 |
GCLM
GLCLR |
glutamate-cysteine ligase, modifier subunit (EC:6.3.2.2) | Ursodeoxycholic Acid results in increased expression of GCLM mRNA |
increases expression
|
mRNA |
19073151
|
| D014580 | 100119944 | Ursodeoxycholic Acid affects the localization of GR1 protein |
affects localization
|
protein |
21158453
|
||
| D014580 | 100119944 | [Ursodeoxycholic Acid co-treated with Dexamethasone] promotes the reaction [EP300 protein binds to GR1 protein binds to HNF1A protein binds to SLC4A2 promoter alternative form] |
affects binding
/ affects cotreatment / increases reaction |
protein |
18188457
|
||
| D014580 | 100119944 | [Ursodeoxycholic Acid co-treated with Dexamethasone] promotes the reaction [GR1 protein binds to SLC4A2 promoter alternative form] |
affects binding
/ affects cotreatment / increases reaction |
protein |
18188457
|
||
| D014580 | 100119944 | [Ursodeoxycholic Acid co-treated with Dexamethasone] promotes the reaction [HNF1A protein binds to GR1 protein binds to SLC4A2 promoter] |
affects binding
/ affects cotreatment / increases reaction |
protein |
18188457
|
||
| D014580 | 100119944 | [Ursodeoxycholic Acid co-treated with Dexamethasone] promotes the reaction [HNF1B protein binds to GR1 protein binds to EP300 protein binds to SLC4A2 promoter alternative form] |
affects binding
/ affects cotreatment / increases reaction |
protein |
18188457
|
||
| D014580 | 100119944 | [Ursodeoxycholic Acid co-treated with Dexamethasone] results in increased localization of GR1 protein |
affects cotreatment
/ increases localization |
protein |
18188457
|
||
| D014580 | 100119944 | [Ursodeoxycholic Acid co-treated with GR1] results in decreased expression of HLA-DRA mRNA |
affects cotreatment
/ decreases expression |
8568266
|
|||
| D014580 | 100119944 | Ursodeoxycholic Acid results in increased localization of GR1 protein |
increases localization
|
protein |
8568266
18188457 |
||
| D014580 | 2937 |
GSS
GSHS |
glutathione synthetase (EC:6.3.2.3) | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Ursodeoxycholic Acid results in increased expression of GSS mRNA] |
decreases reaction
/ increases expression |
mRNA |
19073151
|
| D014580 | 2937 |
GSS
GSHS |
glutathione synthetase (EC:6.3.2.3) | Ursodeoxycholic Acid inhibits the reaction [Iron results in decreased expression of GSS mRNA] |
decreases expression
/ decreases reaction |
mRNA |
19073151
|
| D014580 | 2937 |
GSS
GSHS |
glutathione synthetase (EC:6.3.2.3) | Ursodeoxycholic Acid results in increased expression of GSS mRNA |
increases expression
|
mRNA |
19073151
|
| D014580 | 3082 |
HGF
DFNB39 F-TCF HGFB HPTA SF |
hepatocyte growth factor (hepapoietin A; scatter factor) | Ursodeoxycholic Acid inhibits the reaction [Cholera Toxin results in increased expression of HGF mRNA] |
decreases reaction
/ increases expression |
mRNA |
15802798
|
| D014580 | 3082 |
HGF
DFNB39 F-TCF HGFB HPTA SF |
hepatocyte growth factor (hepapoietin A; scatter factor) | Ursodeoxycholic Acid inhibits the reaction [Cholera Toxin results in increased expression of HGF protein] |
decreases reaction
/ increases expression |
protein |
15802798
|
| D014580 | 3082 |
HGF
DFNB39 F-TCF HGFB HPTA SF |
hepatocyte growth factor (hepapoietin A; scatter factor) | Ursodeoxycholic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of HGF mRNA] |
decreases reaction
/ increases expression |
mRNA |
15802798
|
| D014580 | 3082 |
HGF
DFNB39 F-TCF HGFB HPTA SF |
hepatocyte growth factor (hepapoietin A; scatter factor) | Ursodeoxycholic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of HGF protein] |
decreases reaction
/ increases expression |
protein |
15802798
|
| D014580 | 3122 |
HLA-DRA
HLA-DRA1 MLRW |
major histocompatibility complex, class II, DR alpha | [Ursodeoxycholic Acid co-treated with GR1] results in decreased expression of HLA-DRA mRNA |
affects cotreatment
/ decreases expression |
mRNA |
8568266
|
| D014580 | 3122 |
HLA-DRA
HLA-DRA1 MLRW |
major histocompatibility complex, class II, DR alpha | Ursodeoxycholic Acid inhibits the reaction [IFNG results in increased expression of HLA-DRA mRNA] |
decreases reaction
/ increases expression |
mRNA |
8568266
|
| D014580 | 3122 |
HLA-DRA
HLA-DRA1 MLRW |
major histocompatibility complex, class II, DR alpha | Ursodeoxycholic Acid results in increased expression of HLA-DRA mRNA |
increases expression
|
mRNA |
8568266
|
| D014580 | 6927 |
HNF1A
HNF-1A HNF1 IDDM20 LFB1 MODY3 TCF-1 TCF1 |
HNF1 homeobox A | [Ursodeoxycholic Acid co-treated with Dexamethasone] promotes the reaction [EP300 protein binds to GR1 protein binds to HNF1A protein binds to SLC4A2 promoter alternative form] |
affects binding
/ affects cotreatment / increases reaction |
protein |
18188457
|
| D014580 | 6927 |
HNF1A
HNF-1A HNF1 IDDM20 LFB1 MODY3 TCF-1 TCF1 |
HNF1 homeobox A | [Ursodeoxycholic Acid co-treated with Dexamethasone] promotes the reaction [HNF1A protein binds to GR1 protein binds to SLC4A2 promoter] |
affects binding
/ affects cotreatment / increases reaction |
protein |
18188457
|
| D014580 | 6927 |
HNF1A
HNF-1A HNF1 IDDM20 LFB1 MODY3 TCF-1 TCF1 |
HNF1 homeobox A | [Ursodeoxycholic Acid co-treated with Dexamethasone] promotes the reaction [HNF1A protein binds to SLC4A2 promoter] |
affects binding
/ affects cotreatment / increases reaction |
protein |
18188457
|
| D014580 | 6927 |
HNF1A
HNF-1A HNF1 IDDM20 LFB1 MODY3 TCF-1 TCF1 |
HNF1 homeobox A | [Ursodeoxycholic Acid co-treated with Dexamethasone] promotes the reaction [HNF1A protein binds to SLC4A2 promoter alternative form] |
affects binding
/ affects cotreatment / increases reaction |
protein |
18188457
|
| D014580 | 6927 |
HNF1A
HNF-1A HNF1 IDDM20 LFB1 MODY3 TCF-1 TCF1 |
HNF1 homeobox A | Ursodeoxycholic Acid promotes the reaction [HNF1A protein binds to SLC4A2 promoter] |
affects binding
/ increases reaction |
protein |
18188457
|
| D014580 | 6928 |
HNF1B
FJHN HNF-1B HNF1beta HNF2 HPC11 LF-B3 LFB3 MODY5 TCF-2 TCF2 VHNF1 |
HNF1 homeobox B | [Ursodeoxycholic Acid co-treated with Dexamethasone] promotes the reaction [HNF1B protein binds to GR1 protein binds to EP300 protein binds to SLC4A2 promoter alternative form] |
affects binding
/ affects cotreatment / increases reaction |
protein |
18188457
|
| D014580 | 3385 |
ICAM3
CD50 CDW50 ICAM-R |
intercellular adhesion molecule 3 | Ursodeoxycholic Acid affects the expression of ICAM3 mRNA |
affects expression
|
mRNA |
18422935
|
| D014580 | 3458 |
IFNG
IFG IFI |
interferon, gamma | Ursodeoxycholic Acid inhibits the reaction [IFNG results in increased expression of HLA-DRA mRNA] |
decreases reaction
/ increases expression |
8568266
|
|
| D014580 | 3569 |
IL6
BSF2 HGF HSF IFNB2 IL-6 |
interleukin 6 (interferon, beta 2) | Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of IL6 mRNA]] |
decreases reaction
/ increases expression / increases reaction |
mRNA |
21146893
|
| D014580 | 3569 |
IL6
BSF2 HGF HSF IFNB2 IL-6 |
interleukin 6 (interferon, beta 2) | Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased secretion of IL6 protein]] |
decreases reaction
/ increases reaction / increases secretion |
protein |
21146893
|
| D014580 | 3576 |
IL8
CXCL8 GCP-1 GCP1 LECT LUCT LYNAP MDNCF MONAP NAF NAP-1 NAP1 |
interleukin 8 | Ursodeoxycholic Acid analog inhibits the reaction [[TNF protein co-treated with Cycloheximide] results in increased secretion of IL8 protein] |
affects cotreatment
/ decreases reaction / increases secretion |
protein |
21146893
|
| D014580 | 3576 |
IL8
CXCL8 GCP-1 GCP1 LECT LUCT LYNAP MDNCF MONAP NAF NAP-1 NAP1 |
interleukin 8 | Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of IL8 mRNA]] |
decreases reaction
/ increases expression / increases reaction |
mRNA |
21146893
|
| D014580 | 3615 |
IMPDH2
IMPD2 IMPDH-II |
IMP (inosine 5'-monophosphate) dehydrogenase 2 (EC:1.1.1.205) | Ursodeoxycholic Acid affects the expression of IMPDH2 mRNA |
affects expression
|
mRNA |
18422935
|
| D014580 | 3713 |
IVL
|
involucrin | Ursodeoxycholic Acid results in decreased expression of IVL protein |
decreases expression
|
protein |
10769631
|
| D014580 | 5594 |
MAPK1
ERK ERK2 ERT1 MAPK2 P42MAPK PRKM1 PRKM2 p38 p40 p41 p41mapk |
mitogen-activated protein kinase 1 (EC:2.7.11.24) | Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased phosphorylation of and results in increased activity of MAPK1 protein] |
decreases reaction
/ increases activity / increases phosphorylation |
protein |
14747693
|
| D014580 | 5595 |
MAPK3
ERK-1 ERK1 ERT2 HS44KDAP HUMKER1A P44ERK1 P44MAPK PRKM3 p44-ERK1 p44-MAPK |
mitogen-activated protein kinase 3 (EC:2.7.11.24) | Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
decreases reaction
/ increases activity / increases phosphorylation |
protein |
14747693
|
| D014580 | 4155 |
MBP
|
myelin basic protein | Ursodeoxycholic Acid affects the expression of MBP mRNA |
affects expression
|
mRNA |
18422935
|
| D014580 | 4170 |
MCL1
BCL2L3 EAT MCL1-ES MCL1L MCL1S Mcl-1 TM bcl2-L-3 mcl1/EAT |
myeloid cell leukemia sequence 1 (BCL2-related) | Ursodeoxycholic Acid analog results in increased expression of MCL1 protein |
increases expression
|
protein |
21146893
|
| D014580 | 4193 |
MDM2
ACTFS HDMX hdm2 |
MDM2 oncogene, E3 ubiquitin protein ligase | MDM2 mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased ubiquitination of TP53 protein] |
decreases reaction
/ increases ubiquitination |
mutant form |
20807506
|
| D014580 | 406991 |
MIR21
MIRN21 hsa-mir-21 miR-21 miRNA21 |
microRNA 21 | Ursodeoxycholic Acid results in increased expression of MIR21 mRNA |
increases expression
|
mRNA |
20689055
|
| D014580 | 4673 |
NAP1L1
NAP1 NAP1L NRP |
nucleosome assembly protein 1-like 1 | Ursodeoxycholic Acid affects the expression of NAP1L1 mRNA |
affects expression
|
mRNA |
18422935
|
| D014580 | 283131 |
NEAT1
LINC00084 NCRNA00084 TncRNA VINC |
nuclear paraspeckle assembly transcript 1 (non-protein coding) | Ursodeoxycholic Acid affects the expression of NEAT1 mRNA |
affects expression
|
mRNA |
18422935
|
| D014580 | 4780 |
NFE2L2
NRF2 |
nuclear factor, erythroid 2-like 2 | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Ursodeoxycholic Acid results in increased localization of NFE2L2 protein] |
decreases reaction
/ increases localization |
protein |
19073151
|
| D014580 | 4780 |
NFE2L2
NRF2 |
nuclear factor, erythroid 2-like 2 | Ursodeoxycholic Acid results in increased localization of NFE2L2 protein |
increases localization
|
protein |
19073151
|
| D014580 | 4790 |
NFKB1
EBP-1 KBF1 NF-kB1 NF-kappa-B NF-kappaB NFKB-p105 NFKB-p50 NFkappaB p105 p50 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 | Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of NFKB1 mRNA]] |
decreases reaction
/ increases expression / increases reaction |
mRNA |
21146893
|
| D014580 | 8431 |
NR0B2
SHP SHP1 |
nuclear receptor subfamily 0, group B, member 2 | Ursodeoxycholic Acid results in increased expression of NR0B2 mRNA |
increases expression
|
mRNA |
18706437
|
| D014580 | 9971 |
NR1H4
BAR FXR HRR-1 HRR1 RIP14 |
nuclear receptor subfamily 1, group H, member 4 | Chenodeoxycholic Acid inhibits the reaction [Ursodeoxycholic Acid binds to NR1H4 protein] |
affects binding
/ decreases reaction |
protein |
15935148
|
| D014580 | 9971 |
NR1H4
BAR FXR HRR-1 HRR1 RIP14 |
nuclear receptor subfamily 1, group H, member 4 | Ursodeoxycholic Acid binds to NR1H4 protein |
affects binding
|
protein |
15935148
|
| D014580 | 9971 |
NR1H4
BAR FXR HRR-1 HRR1 RIP14 |
nuclear receptor subfamily 1, group H, member 4 | Ursodeoxycholic Acid results in increased activity of NR1H4 protein |
increases activity
|
protein |
17567710
|
| D014580 | 9971 |
NR1H4
BAR FXR HRR-1 HRR1 RIP14 |
nuclear receptor subfamily 1, group H, member 4 | Ursodeoxycholic Acid results in increased expression of NR1H4 mRNA |
increases expression
|
mRNA |
18706437
|
| D014580 | 9971 |
NR1H4
BAR FXR HRR-1 HRR1 RIP14 |
nuclear receptor subfamily 1, group H, member 4 | Ursodeoxycholic Acid results in increased expression of NR1H4 protein |
increases expression
|
protein |
14684751
|
| D014580 | 8856 |
NR1I2
BXR ONR1 PAR PAR1 PAR2 PARq PRR PXR SAR SXR |
nuclear receptor subfamily 1, group I, member 2 | Ursodeoxycholic Acid results in increased expression of NR1I2 mRNA |
increases expression
|
mRNA |
18706437
|
| D014580 | 220323 |
OAF
NS5ATP13TP2 |
OAF homolog (Drosophila) | Ursodeoxycholic Acid affects the expression of OAF mRNA |
affects expression
|
mRNA |
18422935
|
| D014580 | 5005 |
ORM2
AGP-B AGP-B' AGP2 |
orosomucoid 2 | Ursodeoxycholic Acid affects the expression of ORM2 mRNA |
affects expression
|
mRNA |
18422935
|
| D014580 | 142 |
PARP1
ADPRT ADPRT_1 ADPRT1 ARTD1 PARP PARP-1 PPOL pADPRT-1 |
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) | benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Ursodeoxycholic Acid results in increased cleavage of PARP1 protein] |
decreases reaction
/ increases cleavage |
protein |
21362627
|
| D014580 | 142 |
PARP1
ADPRT ADPRT_1 ADPRT1 ARTD1 PARP PARP-1 PPOL pADPRT-1 |
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) | FADD mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased cleavage of PARP1 protein] |
decreases reaction
/ increases cleavage |
protein |
21362627
|
| D014580 | 142 |
PARP1
ADPRT ADPRT_1 ADPRT1 ARTD1 PARP PARP-1 PPOL pADPRT-1 |
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) | methyl-beta-cyclodextrin inhibits the reaction [Ursodeoxycholic Acid results in increased cleavage of PARP1 protein] |
decreases reaction
/ increases cleavage |
protein |
21362627
|
| D014580 | 142 |
PARP1
ADPRT ADPRT_1 ADPRT1 ARTD1 PARP PARP-1 PPOL pADPRT-1 |
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) | [oxaliplatin co-treated with Ursodeoxycholic Acid] results in increased cleavage of PARP1 protein |
affects cotreatment
/ increases cleavage |
protein |
19728331
|
| D014580 | 142 |
PARP1
ADPRT ADPRT_1 ADPRT1 ARTD1 PARP PARP-1 PPOL pADPRT-1 |
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) | RIPK1 mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased cleavage of PARP1 protein] |
decreases reaction
/ increases cleavage |
protein |
21362627
|
| D014580 | 142 |
PARP1
ADPRT ADPRT_1 ADPRT1 ARTD1 PARP PARP-1 PPOL pADPRT-1 |
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) | TNFRSF10B mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased cleavage of PARP1 protein] |
decreases reaction
/ increases cleavage |
protein |
21362627
|
| D014580 | 142 |
PARP1
ADPRT ADPRT_1 ADPRT1 ARTD1 PARP PARP-1 PPOL pADPRT-1 |
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) | Ursodeoxycholic Acid results in increased cleavage of PARP1 protein |
increases cleavage
|
protein |
21362627
|
| D014580 | 5579 |
PRKCB
PKC-beta PKCB PRKCB1 PRKCB2 |
protein kinase C, beta (EC:2.7.11.13) | Ursodeoxycholic Acid results in increased activity of PRKCB protein |
increases activity
|
protein |
7705931
|
| D014580 | 5580 |
PRKCD
MAY1 PKCD nPKC-delta |
protein kinase C, delta (EC:2.7.10.2 2.7.11.13) | Acetylcysteine inhibits the reaction [Ursodeoxycholic Acid results in increased localization of PRKCD protein] |
decreases reaction
/ increases localization |
protein |
21362627
|
| D014580 | 5580 |
PRKCD
MAY1 PKCD nPKC-delta |
protein kinase C, delta (EC:2.7.10.2 2.7.11.13) | Butylated Hydroxyanisole inhibits the reaction [Ursodeoxycholic Acid results in increased localization of PRKCD protein] |
decreases reaction
/ increases localization |
protein |
21362627
|
| D014580 | 5580 |
PRKCD
MAY1 PKCD nPKC-delta |
protein kinase C, delta (EC:2.7.10.2 2.7.11.13) | diphenyleneiodonium inhibits the reaction [Ursodeoxycholic Acid results in increased localization of PRKCD protein] |
decreases reaction
/ increases localization |
protein |
21362627
|
| D014580 | 5580 |
PRKCD
MAY1 PKCD nPKC-delta |
protein kinase C, delta (EC:2.7.10.2 2.7.11.13) | methyl-beta-cyclodextrin inhibits the reaction [Ursodeoxycholic Acid results in increased localization of PRKCD protein] |
decreases reaction
/ increases localization |
protein |
21362627
|
| D014580 | 5580 |
PRKCD
MAY1 PKCD nPKC-delta |
protein kinase C, delta (EC:2.7.10.2 2.7.11.13) | PRKCD results in increased susceptibility to Ursodeoxycholic Acid |
increases response to substance
|
21362627
|
|
| D014580 | 5580 |
PRKCD
MAY1 PKCD nPKC-delta |
protein kinase C, delta (EC:2.7.10.2 2.7.11.13) | Ursodeoxycholic Acid results in increased localization of PRKCD protein |
increases localization
|
protein |
21362627
|
| D014580 | 5743 |
PTGS2
COX-2 COX2 GRIPGHS PGG/HS PGHS-2 PHS-2 hCox-2 |
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) | Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased expression of PTGS2] |
decreases reaction
/ increases expression |
18444174
|
|
| D014580 | 5879 |
RAC1
Rac-1 TC-25 p21-Rac1 |
ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1) | RAC1 mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased expression of TNFRSF10B] |
decreases reaction
/ increases expression |
mutant form |
21362627
|
| D014580 | 5879 |
RAC1
Rac-1 TC-25 p21-Rac1 |
ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1) | Ursodeoxycholic Acid affects the expression of RAC1 mRNA |
affects expression
|
mRNA |
18422935
|
| D014580 | 5894 |
RAF1
CRAF NS5 Raf-1 c-Raf |
v-raf-1 murine leukemia viral oncogene homolog 1 (EC:2.7.11.1) | Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased phosphorylation of and results in increased activity of RAF1 protein] |
decreases reaction
/ increases activity / increases phosphorylation |
protein |
14747693
|
| D014580 | 5925 |
RB1
OSRC RB p105-Rb pRb pp110 |
retinoblastoma 1 | Ursodeoxycholic Acid results in decreased expression of RB1 protein modified form |
decreases expression
|
protein |
17461466
|
| D014580 | 5930 |
RBBP6
MY038 P2P-R PACT RBQ-1 SNAMA |
retinoblastoma binding protein 6 | Ursodeoxycholic Acid affects the expression of RBBP6 mRNA |
affects expression
|
mRNA |
18422935
|
| D014580 | 117584 |
RFFL
CARP-2 CARP2 FRING RIFIFYLIN RNF189 RNF34L |
ring finger and FYVE-like domain containing E3 ubiquitin protein ligase | Ursodeoxycholic Acid affects the expression of RFFL mRNA |
affects expression
|
mRNA |
18422935
|
| D014580 | 387 |
RHOA
ARH12 ARHA RHO12 RHOH12 |
ras homolog family member A | DLC1 mutant form inhibits the reaction [Ursodeoxycholic Acid results in decreased activity of RHOA protein] |
decreases activity
/ decreases reaction |
protein |
21455586
|
| D014580 | 387 |
RHOA
ARH12 ARHA RHO12 RHOH12 |
ras homolog family member A | Ursodeoxycholic Acid results in decreased activity of RHOA protein |
decreases activity
|
protein |
21455586
|
| D014580 | 22836 |
RHOBTB3
|
Rho-related BTB domain containing 3 | Ursodeoxycholic Acid affects the expression of RHOBTB3 mRNA |
affects expression
|
mRNA |
18422935
|
| D014580 | 8737 |
RIPK1
RIP RIP1 |
receptor (TNFRSF)-interacting serine-threonine kinase 1 (EC:2.7.11.1) | RIPK1 mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased activity of CASP8 protein] |
decreases reaction
/ increases activity |
mutant form |
21362627
|
| D014580 | 8737 |
RIPK1
RIP RIP1 |
receptor (TNFRSF)-interacting serine-threonine kinase 1 (EC:2.7.11.1) | RIPK1 mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased cleavage of CASP3 protein] |
decreases reaction
/ increases cleavage |
mutant form |
21362627
|
| D014580 | 8737 |
RIPK1
RIP RIP1 |
receptor (TNFRSF)-interacting serine-threonine kinase 1 (EC:2.7.11.1) | RIPK1 mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased cleavage of CASP6 protein] |
decreases reaction
/ increases cleavage |
mutant form |
21362627
|
| D014580 | 8737 |
RIPK1
RIP RIP1 |
receptor (TNFRSF)-interacting serine-threonine kinase 1 (EC:2.7.11.1) | RIPK1 mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased cleavage of PARP1 protein] |
decreases reaction
/ increases cleavage |
mutant form |
21362627
|
| D014580 | 6134 |
RPL10
AUTSX5 DXS648 DXS648E L10 NOV QM |
ribosomal protein L10 | Ursodeoxycholic Acid affects the expression of RPL10 mRNA |
affects expression
|
mRNA |
18422935
|
| D014580 | 6155 |
RPL27
L27 |
ribosomal protein L27 (EC:3.6.5.3) | Ursodeoxycholic Acid affects the expression of RPL27 mRNA |
affects expression
|
mRNA |
18422935
|
| D014580 | 6161 |
RPL32
L32 |
ribosomal protein L32 | Ursodeoxycholic Acid affects the expression of RPL32 mRNA |
affects expression
|
mRNA |
18422935
|
| D014580 | 6165 |
RPL35A
DBA5 L35A |
ribosomal protein L35a | Ursodeoxycholic Acid affects the expression of RPL35A mRNA |
affects expression
|
mRNA |
18422935
|
| D014580 | 116832 |
RPL39L
RPL39L1 |
ribosomal protein L39-like | Ursodeoxycholic Acid affects the expression of RPL39L mRNA |
affects expression
|
mRNA |
18422935
|
| D014580 | 6128 |
RPL6
L6 SHUJUN-2 TAXREB107 TXREB1 |
ribosomal protein L6 | Ursodeoxycholic Acid affects the expression of RPL6 mRNA |
affects expression
|
mRNA |
18422935
|
| D014580 | 6181 |
RPLP2
D11S2243E LP2 P2 RPP2 |
ribosomal protein, large, P2 | Ursodeoxycholic Acid affects the expression of RPLP2 mRNA |
affects expression
|
mRNA |
18422935
|
| D014580 | 6207 |
RPS13
S13 |
ribosomal protein S13 (EC:3.6.5.3) | Ursodeoxycholic Acid affects the expression of RPS13 mRNA |
affects expression
|
mRNA |
18422935
|
| D014580 | 51065 |
RPS27L
|
ribosomal protein S27-like | Ursodeoxycholic Acid affects the expression of RPS27L mRNA |
affects expression
|
mRNA |
18422935
|
| D014580 | 6234 |
RPS28
S28 |
ribosomal protein S28 | Ursodeoxycholic Acid affects the expression of RPS28 mRNA |
affects expression
|
mRNA |
18422935
|
| D014580 | 145767 | Ursodeoxycholic Acid affects the expression of RPS3AP6 mRNA |
affects expression
|
mRNA |
18422935
|
||
| D014580 | 55095 |
SAMD4B
SMGB hSmaug2 |
sterile alpha motif domain containing 4B | Ursodeoxycholic Acid affects the expression of SAMD4B mRNA |
affects expression
|
mRNA |
18422935
|
| D014580 | 23451 |
SF3B1
Hsh155 MDS PRP10 PRPF10 SAP155 SF3b155 |
splicing factor 3b, subunit 1, 155kDa | Ursodeoxycholic Acid affects the expression of SF3B1 mRNA |
affects expression
|
mRNA |
18422935
|
| D014580 | 9963 |
SLC23A1
SLC23A2 SVCT1 YSPL3 |
solute carrier family 23 (ascorbic acid transporter), member 1 | Ursodeoxycholic Acid results in increased expression of SLC23A1 mRNA |
increases expression
|
mRNA |
18706437
|
| D014580 | 9962 |
SLC23A2
NBTL1 SLC23A1 SVCT2 YSPL2 |
solute carrier family 23 (ascorbic acid transporter), member 2 | Ursodeoxycholic Acid results in increased expression of SLC23A2 mRNA |
increases expression
|
mRNA |
18706437
|
| D014580 | 292 |
SLC25A5
2F1 AAC2 ANT2 T2 T3 |
solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 5 | Ursodeoxycholic Acid affects the expression of SLC25A5 mRNA |
affects expression
|
mRNA |
18422935
|
| D014580 | 6522 |
SLC4A2
AE2 BND3L EPB3L1 HKB3 NBND3 |
solute carrier family 4 (anion exchanger), member 2 | [Ursodeoxycholic Acid co-treated with Dexamethasone] promotes the reaction [EP300 protein binds to GR1 protein binds to HNF1A protein binds to SLC4A2 promoter alternative form] |
affects binding
/ affects cotreatment / increases reaction |
promoter |
18188457
|
| D014580 | 6522 |
SLC4A2
AE2 BND3L EPB3L1 HKB3 NBND3 |
solute carrier family 4 (anion exchanger), member 2 | [Ursodeoxycholic Acid co-treated with Dexamethasone] promotes the reaction [EP300 protein binds to SLC4A2 promoter] |
affects binding
/ affects cotreatment / increases reaction |
promoter |
18188457
|
| D014580 | 6522 |
SLC4A2
AE2 BND3L EPB3L1 HKB3 NBND3 |
solute carrier family 4 (anion exchanger), member 2 | [Ursodeoxycholic Acid co-treated with Dexamethasone] promotes the reaction [EP300 protein binds to SLC4A2 promoter alternative form] |
affects binding
/ affects cotreatment / increases reaction |
promoter |
18188457
|
| D014580 | 6522 |
SLC4A2
AE2 BND3L EPB3L1 HKB3 NBND3 |
solute carrier family 4 (anion exchanger), member 2 | [Ursodeoxycholic Acid co-treated with Dexamethasone] promotes the reaction [GR1 protein binds to SLC4A2 promoter alternative form] |
affects binding
/ affects cotreatment / increases reaction |
promoter |
18188457
|
| D014580 | 6522 |
SLC4A2
AE2 BND3L EPB3L1 HKB3 NBND3 |
solute carrier family 4 (anion exchanger), member 2 | [Ursodeoxycholic Acid co-treated with Dexamethasone] promotes the reaction [HNF1A protein binds to GR1 protein binds to SLC4A2 promoter] |
affects binding
/ affects cotreatment / increases reaction |
promoter |
18188457
|
| D014580 | 6522 |
SLC4A2
AE2 BND3L EPB3L1 HKB3 NBND3 |
solute carrier family 4 (anion exchanger), member 2 | [Ursodeoxycholic Acid co-treated with Dexamethasone] promotes the reaction [HNF1A protein binds to SLC4A2 promoter] |
affects binding
/ affects cotreatment / increases reaction |
promoter |
18188457
|
| D014580 | 6522 |
SLC4A2
AE2 BND3L EPB3L1 HKB3 NBND3 |
solute carrier family 4 (anion exchanger), member 2 | [Ursodeoxycholic Acid co-treated with Dexamethasone] promotes the reaction [HNF1A protein binds to SLC4A2 promoter alternative form] |
affects binding
/ affects cotreatment / increases reaction |
promoter |
18188457
|
| D014580 | 6522 |
SLC4A2
AE2 BND3L EPB3L1 HKB3 NBND3 |
solute carrier family 4 (anion exchanger), member 2 | [Ursodeoxycholic Acid co-treated with Dexamethasone] promotes the reaction [HNF1B protein binds to GR1 protein binds to EP300 protein binds to SLC4A2 promoter alternative form] |
affects binding
/ affects cotreatment / increases reaction |
promoter |
18188457
|
| D014580 | 6522 |
SLC4A2
AE2 BND3L EPB3L1 HKB3 NBND3 |
solute carrier family 4 (anion exchanger), member 2 | [Ursodeoxycholic Acid co-treated with Dexamethasone] results in increased activity of SLC4A2 protein |
affects cotreatment
/ increases activity |
protein |
18188457
|
| D014580 | 6522 |
SLC4A2
AE2 BND3L EPB3L1 HKB3 NBND3 |
solute carrier family 4 (anion exchanger), member 2 | [Ursodeoxycholic Acid co-treated with Dexamethasone] results in increased expression of SLC4A2 mRNA alternative form |
affects cotreatment
/ increases expression |
mRNA |
18188457
|
| D014580 | 6522 |
SLC4A2
AE2 BND3L EPB3L1 HKB3 NBND3 |
solute carrier family 4 (anion exchanger), member 2 | Ursodeoxycholic Acid promotes the reaction [EP300 protein binds to SLC4A2 promoter] |
affects binding
/ increases reaction |
promoter |
18188457
|
| D014580 | 6522 |
SLC4A2
AE2 BND3L EPB3L1 HKB3 NBND3 |
solute carrier family 4 (anion exchanger), member 2 | Ursodeoxycholic Acid promotes the reaction [HNF1A protein binds to SLC4A2 promoter] |
affects binding
/ increases reaction |
promoter |
18188457
|
| D014580 | 81848 |
SPRY4
HH17 |
sprouty homolog 4 (Drosophila) | Ursodeoxycholic Acid affects the expression of SPRY4 mRNA |
affects expression
|
mRNA |
18422935
|
| D014580 | 6742 |
SSBP1
Mt-SSB SOSS-B1 SSBP mtSSB |
single-stranded DNA binding protein 1, mitochondrial | Ursodeoxycholic Acid affects the expression of SSBP1 mRNA |
affects expression
|
mRNA |
18422935
|
| D014580 | 6772 |
STAT1
CANDF7 ISGF-3 STAT91 |
signal transducer and activator of transcription 1, 91kDa | [Amantadine co-treated with Ursodeoxycholic Acid co-treated with 7,7'-dimethoxy-(4,4'-bi-1,3-benzodioxole)-5,5'-dicarboxylic acid dimethyl ester] results in increased activity of STAT1 |
affects cotreatment
/ increases activity |
15918519
|
|
| D014580 | 6788 |
STK3
KRS1 MST2 |
serine/threonine kinase 3 (EC:2.7.11.1) | Ursodeoxycholic Acid affects the expression of STK3 mRNA |
affects expression
|
mRNA |
18422935
|
| D014580 | 7124 |
TNF
DIF TNF-alpha TNFA TNFSF2 |
tumor necrosis factor | Ursodeoxycholic Acid analog inhibits the reaction [[TNF protein co-treated with Cycloheximide] results in increased secretion of IL8 protein] |
affects cotreatment
/ decreases reaction / increases secretion |
protein |
21146893
|
| D014580 | 7124 |
TNF
DIF TNF-alpha TNFA TNFSF2 |
tumor necrosis factor | Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL2 mRNA]] |
decreases reaction
/ increases expression / increases reaction |
protein |
21146893
|
| D014580 | 7124 |
TNF
DIF TNF-alpha TNFA TNFSF2 |
tumor necrosis factor | Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL5 mRNA]] |
decreases reaction
/ increases expression / increases reaction |
protein |
21146893
|
| D014580 | 7124 |
TNF
DIF TNF-alpha TNFA TNFSF2 |
tumor necrosis factor | Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of IL6 mRNA]] |
decreases reaction
/ increases expression / increases reaction |
protein |
21146893
|
| D014580 | 7124 |
TNF
DIF TNF-alpha TNFA TNFSF2 |
tumor necrosis factor | Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of IL8 mRNA]] |
decreases reaction
/ increases expression / increases reaction |
protein |
21146893
|
| D014580 | 7124 |
TNF
DIF TNF-alpha TNFA TNFSF2 |
tumor necrosis factor | Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of NFKB1 mRNA]] |
decreases reaction
/ increases expression / increases reaction |
protein |
21146893
|
| D014580 | 7124 |
TNF
DIF TNF-alpha TNFA TNFSF2 |
tumor necrosis factor | Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased secretion of IL6 protein]] |
decreases reaction
/ increases reaction / increases secretion |
protein |
21146893
|
| D014580 | 7124 |
TNF
DIF TNF-alpha TNFA TNFSF2 |
tumor necrosis factor | Ursodeoxycholic Acid analog inhibits the reaction [TNF protein results in increased activity of CASP3 protein] |
decreases reaction
/ increases activity |
protein |
21146893
|
| D014580 | 7124 |
TNF
DIF TNF-alpha TNFA TNFSF2 |
tumor necrosis factor | Ursodeoxycholic Acid analog inhibits the reaction [TNF protein results in increased activity of CASP7 protein] |
decreases reaction
/ increases activity |
protein |
21146893
|
| D014580 | 7124 |
TNF
DIF TNF-alpha TNFA TNFSF2 |
tumor necrosis factor | Ursodeoxycholic Acid analog promotes the reaction [[TNF protein co-treated with Cycloheximide] results in increased expression of TNFAIP3 mRNA] |
affects cotreatment
/ increases expression / increases reaction |
protein |
21146893
|
| D014580 | 7128 |
TNFAIP3
A20 OTUD7C TNFA1P2 |
tumor necrosis factor, alpha-induced protein 3 (EC:3.4.19.12) | Ursodeoxycholic Acid analog promotes the reaction [[TNF protein co-treated with Cycloheximide] results in increased expression of TNFAIP3 mRNA] |
affects cotreatment
/ increases expression / increases reaction |
mRNA |
21146893
|
| D014580 | 8795 |
TNFRSF10B
CD262 DR5 KILLER KILLER/DR5 TRAIL-R2 TRAILR2 TRICK2 TRICK2A TRICK2B TRICKB ZTNFR9 |
tumor necrosis factor receptor superfamily, member 10b | Acetylcysteine inhibits the reaction [Ursodeoxycholic Acid results in increased expression of TNFRSF10B] |
decreases reaction
/ increases expression |
21362627
|
|
| D014580 | 8795 |
TNFRSF10B
CD262 DR5 KILLER KILLER/DR5 TRAIL-R2 TRAILR2 TRICK2 TRICK2A TRICK2B TRICKB ZTNFR9 |
tumor necrosis factor receptor superfamily, member 10b | diphenyleneiodonium inhibits the reaction [Ursodeoxycholic Acid results in increased expression of TNFRSF10B] |
decreases reaction
/ increases expression |
21362627
|
|
| D014580 | 8795 |
TNFRSF10B
CD262 DR5 KILLER KILLER/DR5 TRAIL-R2 TRAILR2 TRICK2 TRICK2A TRICK2B TRICKB ZTNFR9 |
tumor necrosis factor receptor superfamily, member 10b | methyl-beta-cyclodextrin inhibits the reaction [Ursodeoxycholic Acid results in increased expression of TNFRSF10B] |
decreases reaction
/ increases expression |
21362627
|
|
| D014580 | 8795 |
TNFRSF10B
CD262 DR5 KILLER KILLER/DR5 TRAIL-R2 TRAILR2 TRICK2 TRICK2A TRICK2B TRICKB ZTNFR9 |
tumor necrosis factor receptor superfamily, member 10b | RAC1 mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased expression of TNFRSF10B] |
decreases reaction
/ increases expression |
21362627
|
|
| D014580 | 8795 |
TNFRSF10B
CD262 DR5 KILLER KILLER/DR5 TRAIL-R2 TRAILR2 TRICK2 TRICK2A TRICK2B TRICKB ZTNFR9 |
tumor necrosis factor receptor superfamily, member 10b | rottlerin inhibits the reaction [Ursodeoxycholic Acid results in increased expression of TNFRSF10B] |
decreases reaction
/ increases expression |
21362627
|
|
| D014580 | 8795 |
TNFRSF10B
CD262 DR5 KILLER KILLER/DR5 TRAIL-R2 TRAILR2 TRICK2 TRICK2A TRICK2B TRICKB ZTNFR9 |
tumor necrosis factor receptor superfamily, member 10b | TNFRSF10B mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased activity of CASP8 protein] |
decreases reaction
/ increases activity |
mutant form |
21362627
|
| D014580 | 8795 |
TNFRSF10B
CD262 DR5 KILLER KILLER/DR5 TRAIL-R2 TRAILR2 TRICK2 TRICK2A TRICK2B TRICKB ZTNFR9 |
tumor necrosis factor receptor superfamily, member 10b | TNFRSF10B mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased cleavage of CASP3 protein] |
decreases reaction
/ increases cleavage |
mutant form |
21362627
|
| D014580 | 8795 |
TNFRSF10B
CD262 DR5 KILLER KILLER/DR5 TRAIL-R2 TRAILR2 TRICK2 TRICK2A TRICK2B TRICKB ZTNFR9 |
tumor necrosis factor receptor superfamily, member 10b | TNFRSF10B mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased cleavage of CASP6 protein] |
decreases reaction
/ increases cleavage |
mutant form |
21362627
|
| D014580 | 8795 |
TNFRSF10B
CD262 DR5 KILLER KILLER/DR5 TRAIL-R2 TRAILR2 TRICK2 TRICK2A TRICK2B TRICKB ZTNFR9 |
tumor necrosis factor receptor superfamily, member 10b | TNFRSF10B mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased cleavage of PARP1 protein] |
decreases reaction
/ increases cleavage |
mutant form |
21362627
|
| D014580 | 8795 |
TNFRSF10B
CD262 DR5 KILLER KILLER/DR5 TRAIL-R2 TRAILR2 TRICK2 TRICK2A TRICK2B TRICKB ZTNFR9 |
tumor necrosis factor receptor superfamily, member 10b | TNFRSF10B results in increased susceptibility to Ursodeoxycholic Acid |
increases response to substance
|
21362627
|
|
| D014580 | 8795 |
TNFRSF10B
CD262 DR5 KILLER KILLER/DR5 TRAIL-R2 TRAILR2 TRICK2 TRICK2A TRICK2B TRICKB ZTNFR9 |
tumor necrosis factor receptor superfamily, member 10b | Ursodeoxycholic Acid results in increased expression of TNFRSF10B mRNA |
increases expression
|
mRNA |
21362627
|
| D014580 | 8795 |
TNFRSF10B
CD262 DR5 KILLER KILLER/DR5 TRAIL-R2 TRAILR2 TRICK2 TRICK2A TRICK2B TRICKB ZTNFR9 |
tumor necrosis factor receptor superfamily, member 10b | Ursodeoxycholic Acid results in increased expression of TNFRSF10B protein |
increases expression
|
protein |
21362627
|
| D014580 | 7157 |
TP53
BCC7 LFS1 P53 TRP53 |
tumor protein p53 | MDM2 mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased ubiquitination of TP53 protein] |
decreases reaction
/ increases ubiquitination |
protein |
20807506
|
| D014580 | 7157 |
TP53
BCC7 LFS1 P53 TRP53 |
tumor protein p53 | TP53 mutant form inhibits the reaction [[oxaliplatin co-treated with Ursodeoxycholic Acid] results in increased activity of CASP3 protein] |
affects cotreatment
/ decreases reaction / increases activity |
mutant form |
19728331
|
| D014580 | 7157 |
TP53
BCC7 LFS1 P53 TRP53 |
tumor protein p53 | TP53 mutant form inhibits the reaction [[oxaliplatin co-treated with Ursodeoxycholic Acid] results in increased activity of CASP8 protein] |
affects cotreatment
/ decreases reaction / increases activity |
mutant form |
19728331
|
| D014580 | 7157 |
TP53
BCC7 LFS1 P53 TRP53 |
tumor protein p53 | Ursodeoxycholic Acid results in increased ubiquitination of TP53 protein |
increases ubiquitination
|
protein |
20807506
|
| D014580 | 55339 |
WDR33
NET14 WDC146 |
WD repeat domain 33 | Ursodeoxycholic Acid affects the expression of WDR33 mRNA |
affects expression
|
mRNA |
18422935
|
Related Disease
Diseases related to proteins in ChEMBL interactions
OMIM (42)
| OMIM | preferred title | UniProt |
|---|---|---|
| #219080 | Acth-independent macronodular adrenal hyperplasia; aimah |
P63092
|
| #612069 | Amyotrophic lateral sclerosis 10, with or without frontotemporal dementia; als10 |
Q13148
|
| #613291 | Bile acid malabsorption, primary; pbam |
Q12908
|
| #115200 | Cardiomyopathy, dilated, 1a; cmd1a |
P02545
|
| #212112 | Cardiomyopathy, dilated, with hypergonadotropic hypogonadism |
P02545
|
| #605588 | Charcot-marie-tooth disease, axonal, type 2b1; cmt2b1 |
P02545
|
| #605479 | Cholestasis, benign recurrent intrahepatic, 2; bric2 |
O95342
|
| #601847 | Cholestasis, progressive familial intrahepatic, 2; pfic2 |
O95342
|
| #127750 | Dementia, lewy body; dlb |
P37840
|
| #609535 | Drug metabolism, poor, cyp2c19-related |
P33261
|
| #608902 | Drug metabolism, poor, cyp2d6-related |
P10635
|
| #237500 | Dubin-johnson syndrome; djs |
Q92887
|
| #181350 | Emery-dreifuss muscular dystrophy 2, autosomal dominant; edmd2 |
P02545
|
| #608013 | Gaucher disease, perinatal lethal |
P04062
|
| #230800 | Gaucher disease, type i |
P04062
|
| #230900 | Gaucher disease, type ii |
P04062
|
| #231000 | Gaucher disease, type iii |
P04062
|
| #231005 | Gaucher disease, type iiic |
P04062
|
| #605130 | Hairy elbows, short stature, facial dysmorphism, and developmental delay |
Q03164
|
| #610140 | Heart-hand syndrome, slovenian type |
P02545
|
| #176670 | Hutchinson-gilford progeria syndrome; hgps |
P02545
|
| #145000 | Hyperparathyroidism 1; hrpt1 |
O00255
|
| #605115 | Hypertension, early-onset, autosomal dominant, with severe exacerbation in pregnancy |
P08235
|
| #151660 | Lipodystrophy, familial partial, type 2; fpld2 |
P02545
|
| #248370 | Mandibuloacral dysplasia with type a lipodystrophy; mada |
P02545
|
| #174800 | Mccune-albright syndrome; mas |
P63092
|
| #131100 | Multiple endocrine neoplasia, type i; men1 |
O00255
|
| #613205 | Muscular dystrophy, congenital, lmna-related |
P02545
|
| #159001 | Muscular dystrophy, limb-girdle, type 1b; lgmd1b |
P02545
|
| #166350 | Osseous heteroplasia, progressive; poh |
P63092
|
| #168601 | Parkinson disease 1, autosomal dominant; park1 |
P37840
|
| #605543 | Parkinson disease 4, autosomal dominant; park4 |
P37840
|
| #168600 | Parkinson disease, late-onset; pd |
P04062
P37840 |
| #102200 | Pituitary adenoma, growth hormone-secreting |
P63092
|
| #177735 | Pseudohypoaldosteronism, type i, autosomal dominant; pha1a |
P08235
|
| #103580 | Pseudohypoparathyroidism, type ia; php1a |
P63092
|
| #603233 | Pseudohypoparathyroidism, type ib; php1b |
P63092
|
| #612462 | Pseudohypoparathyroidism, type ic; php1c |
P63092
|
| #275210 | Restrictive dermopathy, lethal |
P02545
|
| #604906 | Schizophrenia 9; sczd9 |
P49798
|
| #181500 | Schizophrenia; sczd |
P49798
|
| #607250 | Spinocerebellar ataxia, autosomal recessive, with axonal neuropathy; scan1 |
Q9NUW8
|
KEGG DISEASE (36)
| KEGG | disease name | UniProt |
|---|---|---|
| H00033 | Adrenal carcinoma |
O00255
(related)
|
| H00034 | Carcinoid |
O00255
(related)
|
| H00045 | Malignant islet cell carcinoma |
O00255
(related)
|
| H00246 | Primary hyperparathyroidism |
O00255
(related)
|
| H01102 | Pituitary adenomas |
O00255
(related)
|
| H00624 | Familial cholestasis |
O95342
(related)
|
| H00264 | Charcot-Marie-Tooth disease (CMT) |
P02545
(related)
|
| H00294 | Dilated cardiomyopathy (DCM) |
P02545
(related)
|
| H00420 | Familial partial lipodystrophy (FPL) |
P02545
(related)
|
| H00563 | Emery-Dreifuss muscular dystrophy |
P02545
(related)
|
| H00590 | Congenital muscular dystrophies (CMD/MDC) |
P02545
(related)
|
| H00593 | Limb-girdle muscular dystrophy (LGMD) |
P02545
(related)
|
| H00601 | Hutchinson-Gilford progeria syndrome |
P02545
(related)
|
| H00663 | Restrictive dermopathy |
P02545
(related)
|
| H00665 | Mandibuloacral dysplasia |
P02545
(related)
|
| H01216 | Left ventricular noncompaction (LVNC) |
P02545
(related)
|
| H00066 | Lewy body dementia (LBD) |
P04062
(related)
P37840 (related) |
| H00126 | Gaucher disease |
P04062
(related)
|
| H00426 | Defects in the degradation of ganglioside |
P04062
(related)
|
| H00810 | Progressive myoclonic epilepsy (PME) |
P04062
(related)
|
| H00599 | 46,XX disorders of sex development (Disorders related to androgen excess) |
P04150
(related)
|
| H00243 | Hyperkalemic distal renal tubular acidosis (RTA type 4) |
P08235
(related)
|
| H00603 | Hypertension exacerbated in pregnancy |
P08235
(related)
|
| H00036 | Osteosarcoma |
P08684
(marker)
|
| H01205 | Coumarin resistance |
P11712
(related)
|
| H01171 | Poor drug metabolism (PM) |
P33261
(related)
|
| H00057 | Parkinson's disease (PD) |
P37840
(related)
|
| H00244 | Pseudohypoparathyroidism |
P63092
(related)
|
| H00441 | Progressive osseous heteroplasia (POH) |
P63092
(related)
|
| H00501 | Fibrous dysplasia, polyostotic |
P63092
(related)
|
| H00001 | Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia) |
Q03164
(related)
Q03164 (marker) |
| H00002 | Acute lymphoblastic leukemia (ALL) (precursor T lymphoblastic leukemia) |
Q03164
(related)
|
| H01016 | Primary bile acid malabsorption |
Q12908
(related)
|
| H00058 | Amyotrophic lateral sclerosis (ALS) |
Q13148
(related)
|
| H00208 | Hyperbilirubinemia |
Q92887
(related)
|
| H00063 | Spinocerebellar ataxia (SCA) |
Q9NUW8
(related)
|
Diseases related to CTD interactions
39 disease from interactions of metabolites
| MeSH disease | OMIM | compound | disease name | evidence type |
reference
pmid |
|---|---|---|---|---|---|
| D058739 | D014580 | Aberrant Crypt Foci |
therapeutic
|
12636105
|
|
| D001649 | D014580 | Bile Duct Diseases |
therapeutic
|
6345281
|
|
| D002761 | D014580 | Cholangitis |
therapeutic
|
8698195
|
|
| D015209 | D014580 | Cholangitis, Sclerosing |
therapeutic
|
7514624
17489059 |
|
| D002769 | D014580 | Cholelithiasis |
therapeutic
|
1769469
8187305 |
|
| D002779 | D014580 | Cholestasis |
therapeutic
|
1751019
8143756 9411201 9487641 9562975 9857764 11922592 12187295 12532564 15122001 15539232 16487557 19619254 20960257 21274875 21362627 |
|
| D002780 | D014580 | Cholestasis, Intrahepatic |
therapeutic
|
2142412
11034010 11117561 14728856 16205517 17924304 18049162 19744016 |
|
| C535932 | D014580 | Cholestasis, intrahepatic of pregnancy |
therapeutic
|
12606635
|
|
| C535933 | D014580 | Cholestasis, progressive familial intrahepatic 1 |
therapeutic
|
10618887
|
|
| D003110 | D014580 | Colonic Neoplasms |
therapeutic
|
10025872
12496057 17438113 18444174 21362627 |
|
| D003550 | D014580 | Cystic Fibrosis |
therapeutic
|
2391071
|
|
| D056486 | D014580 | Drug-Induced Liver Injury |
therapeutic
|
10453939
11922592 15892770 16205517 |
|
| D005221 | D014580 | Fatigue |
therapeutic
|
10750660
|
|
| D005234 | D014580 | Fatty Liver |
therapeutic
|
22154323
|
|
| D005355 | D014580 | Fibrosis |
therapeutic
|
21274875
21410058 |
|
| D005705 | D014580 | Gallbladder Diseases |
therapeutic
|
18518811
|
|
| D042882 | D014580 | Gallstones |
marker/mechanism
therapeutic |
1518435
2217675 2513036 2689115 6354826 7461467 7593435 7890216 8480875 9641388 18574646 |
|
| D019698 | D014580 | Hepatitis C, Chronic |
therapeutic
|
9058296
19073151 |
|
| D006521 | D014580 | Hepatitis, Chronic |
therapeutic
|
8713707
9717080 |
|
| D006943 | D014580 | Hyperglycemia |
therapeutic
|
22154323
|
|
| D006980 | D014580 | Hyperthyroidism |
therapeutic
|
19534646
|
|
| D007037 | D014580 | Hypothyroidism |
therapeutic
|
18518811
|
|
| D007249 | D014580 | Inflammation |
therapeutic
|
21146893
|
|
| D007333 | D014580 | Insulin Resistance |
therapeutic
|
22154323
|
|
| D007565 | D014580 | Jaundice |
therapeutic
|
7982642
10750660 11669021 16205517 |
|
| D041781 | D014580 | Jaundice, Obstructive |
therapeutic
|
7514624
7751579 |
|
| D008103 | D014580 | Liver Cirrhosis |
marker/mechanism
therapeutic |
3470420
8713707 |
|
| D008105 | D014580 | Liver Cirrhosis, Biliary |
therapeutic
|
1359888
1882800 1959845 7514624 7814810 8276045 8650973 8713704 8741181 9324169 9717080 9857764 10524634 11577102 12468960 14999689 15710226 15816485 18188457 18422935 19073151 19881358 21410058 22194894 |
|
| D008106 | D014580 | Liver Cirrhosis, Experimental |
therapeutic
|
21274875
21410058 |
|
| D008107 | D014580 | Liver Diseases |
therapeutic
|
2391071
15802798 17888421 19493473 19811448 21115542 |
|
| D017114 | D014580 | Liver Failure, Acute |
therapeutic
|
21146893
|
|
| D009078 | D014580 | Mucocele |
therapeutic
|
18518811
|
|
| D009336 | D014580 | Necrosis |
marker/mechanism
therapeutic |
14976352
16432164 17888421 21274875 |
|
| D009369 | D014580 | Neoplasms |
therapeutic
|
21362627
|
|
| D010195 | D014580 | Pancreatitis |
therapeutic
|
16205517
|
|
| D017094 | D014580 | Porphyrias, Hepatic |
therapeutic
|
1751019
|
|
| D011183 | D014580 | Postoperative Complications |
therapeutic
|
18574646
|
|
| D011537 | D014580 | Pruritus |
therapeutic
|
10750660
15365421 16205517 |
|
| D015431 | D014580 | Weight Loss |
marker/mechanism
|
21747115
|